



Subject: Drug Testing*

Effective Date: June 20, 2017

Department(s): Utilization Management

Policy: Presumptive and definitive drug testing is reimbursable under plans administered by QualCare, inc. as specified in the procedure section below.

Objective: To ensure proper and consistent reimbursement and appropriate utilization of resources.

Procedure: A. Presumptive drug testing not to exceed one (1) unit per date of service up to 32 units per year is reimbursable as medically necessary when there is a suspicion of drug misuse by the individual being tested, and ALL of the following criteria are met (CPT 80305, 80306, 80307; HCPCS G0477, G0478, G0479):

1. The diagnosis, history and physical exam and/or behavior of the individual being tested support the need for the specific drug testing requested.
2. Testing results will impact treatment.
3. Testing is performed in a physician-supervised treatment setting.

B. Definitive drug testing not to exceed 16 dates of service per year for a maximum of eight(8) units(a unit may include a specific individual drug and/or its metabolite(s), or its structural isomer(s)) per date of service up to 128 units per year is reimbursable as medically necessary when there is a suspicion of drug misuse by the individual being tested, and EITHER of the following criteria are met(HCPCS G0480, G0481, G0659):

CONFIDENTIAL - NOT FOR DISTRIBUTION OUTSIDE OF QUALCARE

1. Presumptive test results are inconsistent with the individual's condition, history and examination.
2. A presumptive drug test is not available for the drug for which there is a suspicion of abuse or misuse and ALL of the following criteria are met:
 - The diagnosis, history and physical examination and/or behavior of the individual being tested support the need for the specific drug testing being requested
 - Testing results will impact treatment
 - Testing is performed in a physician-supervised treatment setting

Definitive drug testing must be performed in a Clinical Laboratory Improvement Amendment([CLIA]-CMS certification)-approved Laboratory to be eligible for reimbursement.

- C. Drug testing by hair analysis is NOT reimbursable because it is experimental, investigational or unproven as there is insufficient evidence in the published peer-reviewed scientific literature to establish the role of hair analysis in clinical drug testing.(HCPCS-P2031)
- D. Any other drug testing to determine drug misuse is not reimbursable, including but not limited to the following because it is considered not medically necessary:
 - Routine tests for confirmation of specimen integrity(urinalysis, creatinine concentration, presence of oxidizing agents, PH, temperature) when billed with drug testing(CPY 81000-81003, 81005, 82570, 83986)
 - testing ordered by or on behalf of third parties (e.g., school, courts, employers)
- E. When billed by an entity that did not perform the service drug testing is not reimbursable.

References:

Kirsh KL, Heit HA, Huskey A, Strickland J, Egan K, Passik SD. Trends in drug use from urine drug testing of addiction treatment clients. *J Opioid Manag.* 2015;11(1):61-8(Jan-Feb).

Hoffman RJ. Testing for drugs of abuse (DOA). Version 9.0 In: UpToDate, Traub SJ (Ed), UpToDate, Waltham, MA

American Society of Addiction Medicine (ASAM). The ASAM national practice guideline for the use of medications in the treatment of addiction involving opioid use. 2015 June 1. Available at URL address: [http://www.asam.org/docs/default-source/practice-support/guidelines-and-consensus-docs/asam-national-practice-guideline-supplement.pdf?sfvrsn=24#search="the asam national practice guideline for the use o"](http://www.asam.org/docs/default-source/practice-support/guidelines-and-consensus-docs/asam-national-practice-guideline-supplement.pdf?sfvrsn=24#search=)

Substance Abuse and Mental Health Services Administration. Federal guidelines for opioid treatment programs. March 2015.. Available at URL address: <http://store.samhsa.gov/shin/content//PEP15-FEDGUIDEOTP/PEP15-FEDGUIDEOTP.pdf>

Nuckols TK, Anderson L, Popescu I, et al. Opioid prescribing: a systematic review and critical appraisal of guidelines for chronic pain. *Ann Intern Med.* 2014;160:38–47

Turner JA, Saunders K, Shortreed SM, LeResche L, et al. Chronic Opioid Therapy Urine Drug Testing in Primary Care: Prevalence and Predictors of Aberrant Results. *J Gen Intern Med.* 2014; 29(12): 1663–1671(Dec)

Dupouy J, Mémier V, Catala H, Lavit M, Oustric S, Lapeyre-Mestre M. Does urine drug abuse screening help for managing patients? A systematic review. *Drug Alcohol Depend.* 2014;136:11-20(Mar)

American Society of Addiction Medicine. Drug testing: a white paper of the American Society of Addiction Medicine (ASAM). 2013 Oct 26. Available at: <http://www.asam.org/docs/default-source/public-policy-statements/-pdf-.pdf?sfvrsn=0>.

Manchikanti L, Abdi S, Atluri S, Balog CC, Benyamin RM, Boswell MV, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part 2 - guidance. *Pain Physician.* 2012;15(3 Suppl):S67-S116(Jul)

Substance Abuse and Mental Health Services Administration. Clinical Drug Testing in Primary Care. Technical Assistance Publication (TAP) 32. HHS Publication No. (SMA) 12-4668. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2012.

Christo PJ, Manchikanti L, Ruan X, Bottros M, Hansen H, Solanki DR, Jordan AE, Colson J. Urine drug testing in chronic pain. *Pain Physician.* 2011;14(2):123-43(Mar-Apr)

American Society of Addiction Medicine (ASAM). (2010). Drug testing as a component of addiction treatment and monitoring programs and in other clinical settings.. Available at URL address: <http://www.asam.org/advocacy/find-a-policy-statement/view-policy-statement/public-policy-statements/2011/12/15/drug-testing-as-a-component-of-addiction-treatment-and-monitoring-programs-and-in-other-clinical-settings>

Starrels JL, Becker WC, Alford DP, Kapoor A, Williams A, Turner BJ. Systematic review: treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. *Ann Intern Med.* 2010;152:712–720

U.S. Preventive Services Task Force. Drug use, illicit: screening. Release date Jan 2008. Available at URL address: [http://www.uspreventiveservicestaskforce.org/Page/Topic/recommendation-summary/drug-use-illicit-screening?ds=1&s=drug screening](http://www.uspreventiveservicestaskforce.org/Page/Topic/recommendation-summary/drug-use-illicit-screening?ds=1&s=drug%20screening)

Drafted By: MMcNeil, MD 05/05/17

Approved By/Date: QM Committee 6/20/17

*Consistent with Summary Plan Description (SPD). When there is discordance between this policy and the SPD, the provisions of the SPD prevail.